Sleep disorders are common in Huntington's disease. They may present as difficulties in falling asleep and/or early awakenings in the middle of the night followed by insomnia — a recognised comorbidity that requires targeted management alongside the primary neurodegenerative condition.
When lifestyle strategies are insufficient, pharmacological options can be considered — with the choice and duration of treatment guided by dependency risk and the specific pattern of sleep disturbance. The complete structured regimen is available in the full protocol.
DOI: 10.3389/fneur.2019.00710